<p>Hengrui Pharma (01276.HK) announced that its HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center, with the intended indication for first-line treatment of advanced or metastatic pancreatic cancer carrying the KRAS G12D mutation in combination with gemcitabine and paclitaxel</p>

600276

01276

516820

513060

<p>Hengrui Pharma announced that its HRS-4642 injection has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center, with the intended indication being the first-line treatment for advanced or metastatic pancreatic cancer carrying the KRAS G12D mutation in combination with gemcitabine and paclitaxel</p>

AASTOCKS

Hengrui Pharma

HENGRUI PHARMA

Ping An CSI Medicine and Medical Device Innovation ETF

Bosera Hang Seng Health Care ETF(QDII)

Hengrui Pharma's HRS-4642 injection has been included in the list of breakthrough therapy designations